The discrepant results of MR studies of Lp(a) for IS subtypes highlight the importance of subtyping of IS outcomes in these Lp(a)-lowering trials.50–52 Assuming that the efficacy and safety of such novel potent Lp(a)-lowering treatments on MI (and some stroke outcomes) are confirmed, this study provides support for extending a precision medicine approach to prioritizing such treatments to high-risk East Asian as well as European patients with high plasma levels of Lp(a). The gene discussed is LPA; the disease is stroke disorder.